Suscripción a Biblioteca: Guest
Critical Reviews™ in Biomedical Engineering

Publicado 6 números por año

ISSN Imprimir: 0278-940X

ISSN En Línea: 1943-619X

SJR: 0.262 SNIP: 0.372 CiteScore™:: 2.2 H-Index: 56

Indexed in

Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma

Volumen 40, Edición 4, 2012, pp. 279-294
DOI: 10.1615/CritRevBiomedEng.v40.i4.40
Get accessGet access

SINOPSIS

Malignant melanoma, the most lethal skin cancer, is considered as a representative model for cross talk between immune responses and malignancy. Efforts to elucidate the nature of these interactions have translated into immunotherapeutic strategies. Adjuvant therapeutics such as IL-2 and IFNα2b have reached clinical application, and emerging therapies targeting key immunomodulatory molecules such as CTLA-4 have renewed excitement in the field, highlighting the potential of manipulating immune responses in the clinical setting, but also the merits for further elucidating complex underlying immunological pathways. Screening technologies have yielded new insights leading to identification of biomarkers for disease prognosis and applied clinical immunotherapies. The promise of systems biology is to integrate diverse biomedical characterizations into detailed models of underlying mechanisms and therapies through suitable computational and mathematical formalisms. In this review, we discuss recent developments in dissecting the complex and diverse immune responses associated with melanoma through both computational and experimental means. We show the significance of devising new, improved approaches that can better serve as models of immune interactions and therapies. We propose that efforts in this direction may realize the potential of personalized medicine and facilitate development of the next generation of efficacious tools to treat patients.

CITADO POR
  1. Cintolo Jessica A., Gimotty Phyllis, Blair Anne, Guerry DuPont, Elder David E., Hammond Rachel, Elenitsas Rosalie, Xu Xiaowei, Fraker Douglas, Schuchter Lynn M., Czerniecki Brian J., Karakousis Giorgos, Local Immune Response Predicts Survival in Patients with Thick (T4) Melanomas, Annals of Surgical Oncology, 20, 11, 2013. Crossref

  2. Pergoli Laura, Favero Chiara, Pfeiffer Ruth M., Tarantini Letizia, Calista Donato, Cavalleri Tommaso, Angelici Laura, Consonni Dario, Bertazzi Pier A., Pesatori Angela C., Landi Maria T., Bollati Valentina, Blood DNA methylation, nevi number, and the risk of melanoma, Melanoma Research, 24, 5, 2014. Crossref

  3. Dahlke Erin, Murray Christian Alexander, Kitchen Jessica, Chan An-Wen, Systematic review of melanoma incidence and prognosis in solid organ transplant recipients, Transplantation Research, 3, 1, 2014. Crossref

  4. Tanase Cristiana, Albulescu Radu, Neagu Monica, Proteomic Approaches for Biomarker Panels in Cancer, Journal of Immunoassay and Immunochemistry, 37, 1, 2016. Crossref

  5. Karagiannis Panagiotis, Villanova Federica, Josephs Debra H, Correa Isabel, Van Hemelrijck Mieke, Hobbs Carl, Saul Louise, Egbuniwe Isioma U, Tosi Isabella, Ilieva Kristina M, Kent Emma, Calonje Eduardo, Harries Mark, Fentiman Ian, Taylor-Papadimitriou Joyce, Burchell Joy, Spicer James F, Lacy Katie E, Nestle Frank O, Karagiannis Sophia N, Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma, OncoImmunology, 4, 11, 2015. Crossref

  6. MALAS SADEK, HARRASSER MICAELA, LACY KATIE E., KARAGIANNIS SOPHIA N., Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review), Oncology Reports, 32, 3, 2014. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain